4577 · Daito Pharmaceutical Co., Ltd. · Financials
Market Cap
37.22B JPY
Shares
28.26M
Volume · Nov 13
50.8K
Avg daily vol (3M)
84.89K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
50.65B
0%
FY2026
Net Income
3.16B
+65.7%
FY2026
Gross Margin
19.54%
+2.5pp
FY2026
Operating Margin
7.18%
+2pp
FY2026
Operating Cash Flow
9.38B
+59%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| JPY | 50.65B | 50.64B | 46.9B | 45.1B | 43.46B |
| JPY | 40.75B | 42.01B | 37.06B | 34.77B | 32.01B |
| JPY | 9.9B | 8.64B | 9.84B | 10.33B | 11.46B |
| JPY | 3.64B | 2.62B | 3.89B | 5.21B | 6.55B |
| JPY | 4.07B | 2.96B | 4.22B | 5.08B | 6.72B |
| JPY | 928M | 1.19B | 1.04B | 1.55B | 2.09B |
| JPY | 3.16B | 1.91B | 3.3B | 3.6B | 4.67B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 4.62B in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.